AAIPharma Services (AAI) and Cambridge Major Laboratories (CML) are now Alcami, a new brand and identity as a contract development and manufacturing organization (CDMO) with expanded capabilities and capacity.

Originally joined together in late 2013, AAI and CML combined to offer analytical testing and development services for active pharmaceutical ingredients (APIs) with oral solid and parenteral dose finished product capacity.

"Alcami" represents the combination of the legacy company names in a contemporary coined name reflective of a transformation to become a worldclass solution provider to meet the growing pipeline of new products in development within the pharmaceutical and biotech industry. Improved quality and regulatory systems as well as operational performance are driving a culture of excellence across seven sites with nearly 1,000 employees in the U.S. and Europe.

Providing an integrated offering for both drug substance and drug product at every development stage beginning with solid state chemistry and formulation development, Alcami believes they have created a robust new outsourcing offering. Alcami also recently announced significant investments in additional capabilities and capacity for oral solid dose manufacturing, and parenteral fill-finish capabilities and capacity, including additional sterile lines and lyophilization capacity available now.